FDA: Tregzi approval press announcement | Source Library

GovernmentU.S. health regulator

Source type: Government
Access type: Official
Publisher: FDA
Date: 2026-06-30
Added: 2026-06-30

Trust profile

VV Source Trust Matrix v1.0

VV Source Trust Matrix v1.0 asks whether this source is trustworthy for the claim lane being used, not whether every possible claim from it is equally strong.

U.S. health regulator

Publisher type: Regulator
Bias profile: Low

This source is strongest for regulatory status and safety and weaker for consumer context and trial discovery.

VV Source Fit Score 1.0

Fit by use case

Fit scores are role-specific. A source can be excellent for one claim lane and weak for another.

Frameworks ->

Regulatory status: 98/100; Primary Anchor
Clinical outcomes: 84/100; Strong Support
Mechanism: 68/100; Context Source
Safety: 95/100; Primary Anchor
Consumer context: 68/100; Context Source
Trial discovery: 68/100; Context Source

Best used for

Approvals
Labels
Safety communications

Weak for

Comparative effectiveness
Consumer experience

Used in Viral Vitalism

Regulatory statusbrief1 reference

FDA Approved a Donor Immune-Cell Therapy to Reduce Serious Transplant Complications

Roles: Regulatory status

Show section-level references

FDA approved Tregzi, a donor-derived regulatory T-cell-based immunotherapy, to improve chronic GVHD-free survival in eligible adult blood-cancer patients undergoing matched-donor allogeneic stem cell transplant.

Related studies

No structured study record is currently attached to this source.